| Asset Classes | Corporate bonds |
|---|---|
| Impact strategy | Impact Equities and Bonds |
| Sector | Healthcare |
| ISIN code | XS1998215393 |
| Industry group | Health Care Equipment & Services |
| Aligned with SDGs |
Baxter provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs etc. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. Baxter International was founded in 1931 by Donald Baxter, a Los Angeles-based medical doctor, as a manufacturer and distributor of intravenous therapy solutions. The company employs around 48,000 people around the world. The company is headquartered in Deerfield, Illinois, United States.
Investment rationale
Worldwide, 1 out of 10 people suffers from some form of chronic kidney disease (CKD). Baxter provides essential healthcare products to treat CDK, including acute and chronic dialysis therapies and infusion systems. Used in healthcare facilities, and directly contributing to to improving people’s health, these products account for 100% of the company’s revenues. Baxter therefore has a good fit with our Prosperous & Healthy People theme. Baxter publishes an annual corporate social responsibility (CSR) report, ion which the company presents the progress on specific CSR programs and targets. Priority targets include reducing material use, increasing packaging efficiency, achieving best record for recordable incidents, and reducing absolute GHG emissions. In 2016, the company established the Baxter International Foundation Partnership Grant program to drive increased access to healthcare for an incremental 10,000 patients annually. In 2019, Baxter Foundation launched two multi-year signature partnerships, investing nearly USD 3 million to support safe surgery for cleft conditions, and promote nutrition to help prevent diabetes.